Hauj lwm lawm

Kev tsis

Taw qhia

Liraglutide2

Factory 2

musclepic 5

Khoom Description

Part 1: Kev faib tawm System

Cov khoom siv raw-qib liraglutide feem ntau tuaj yeem muab faib ua peb pawg hauv qab no raws li nws cov kev xav tau siv thiab kev ua kom huv huv:

I. Pharmaceutical-qib liraglutide raw khoom (API qib)

- Purity Ntau dua lossis sib npaug li 98% (HPLC), qee qhov siab - specifications tuaj yeem ncav cuag ntau dua 99%

- Clear impurity profile, residual solvents thiab hnyav hlau ua raws li kev cai

- Siv rau kev tsim tshuaj xws li txhaj tshuaj thiab cwj mem formulations

- Yuav tsum ua raws li GMP, ICH, pharmacopoeia, thiab lwm yam qauv

II. Laboratory thiab tshawb fawb -qib liraglutide

- Purity 95% ~ 98%

- Feem ntau yog siv rau kev tshawb fawb tshuaj, kev sim ntawm tes, thiab kev tshawb fawb pharmacokinetic

- Kev ruaj ntseg thiab impurity tswj qhov yuav tsum tau qis dua API qib

III. Kev tsim kho engineering- qib liraglutide (rau kev tshawb nrhiav kev tsim)

- Purity 90% ~ 95%

- Siv rau kev tshuaj ntsuam xyuas cov qauv, kev tshawb nrhiav kev tsim qauv ua ntej, thiab kev txhim kho txoj hauv kev

- Tus nqi qis dua, ua kom yooj yim loj- teev ntxov- theem sim

Qhov kev faib tawm no los ntawm kev npaj siv pab pawg tshawb fawb, cov tuam txhab tshuaj, lossis cov chaw sim xaiv cov khoom siv raw zoo tshaj plaws raws li lawv cov peev nyiaj thiab daim ntawv thov scenario.

Ntu 2 Physicochemical Properties

Liraglutide yog polypeptide molecule uas muaj 31 amino acids. Kev hloov kho tom qab ntawm C16 fatty acid sawb txhim kho nws cov ntshav plasma protein khi lub peev xwm, yog li ncua nws ib nrab - lub neej thiab ua tiav ntev - ua tus yam ntxwv rau ib zaug - noj txhua hnub.

Nws cov yam ntxwv physicochemical tsis yog raws li hauv qab no:

- Molecular Formula: C₁₇₂H₂₆₅N₄₃O₅₁

- Molecular Luj: 3751.2 Da

- Cov yam ntxwv ntawm tus qauv:

Highly hydrophilic peptide saw

Fatty acid side chains txhim kho molecular hydrophobicity

Yuav khi rau albumin, ncua kev degradation

- Solubility: Soluble nyob rau hauv dej, buffer solutions, thiab polar solvents; zoo stability ntawm pH 6-8

- Isoelectric Point: Kwv yees li 5.0

- Kev ruaj ntseg:

Lyophilized hmoov yog qhov kub thiab txias -sensitive thiab xav tau cov saw hlau txias cia

Tiv thaiv los ntawm lub teeb thiab tsis txhob rov khov dua -thaw cycles

Ua kom ruaj khov zoo ntawm qhov kub thiab txias hauv lub xeev daws

Kev hloov pauv fatty acid ntawm liraglutide yog ib qho tseem ceeb ntawm cov qauv uas ua rau nws ntev ib nrab - lub neej thiab kev ua tau zoo, uas yog lub hauv paus ntsiab lus vim li cas nws yog tus sawv cev ntawm ntev - ua yeeb yam GLP-1.

Ntu 3: Cov tsos thiab xim yam ntxwv

High-cov ntaub ntawv zoo liraglutide feem ntau yog dawb los tawm -cov hmoov dawb lyophilized. Vim lub ntuj tsim ntawm peptides, lawv cov xim yuav txawv me ntsis ntawm pawg, tab sis tag nrho nws yuav tsum tswj cov hauv qab no:

- Dawb

- Tawm -dawb

- Zoo, zoo ib yam micron- hmoov loj

- Tsis pom impurities

- Tsis muaj xim txawv (ib qho pom daj lossis grey tint tuaj yeem qhia tias muaj oxidation lossis kev ua haujlwm tsis zoo)

High-cov khoom siv raw hmoov zoo feem ntau pom muaj qhov xoob lossis lumpy freeze- cov qauv qhuav, qhia tias khov kom zoo- ziab thiab kev tiv thaiv zoo ntawm tshav kub- rhiab amino acid cov qauv.

Ntu 4: Kev Ntsuam Xyuas Qhov Zoo

Qhov zoo ntawm liraglutide qia tsis yog los ntawm nws cov tshuaj pharmacological nkaus xwb tab sis kuj los ntawm kev tswj hwm purity, kev ruaj ntseg, thiab kev ua kom zoo ntawm cov qauv hauv peptide engineering nws tus kheej. Lub ntsiab zoo yog raws li nram no:

**Ib. Ntev - cov khoom kav ntev vim kev hloov pauv fatty acid:**

- ncua kev degradation los ntawm kev khi rau plasma albumin

- Ib nrab- lub neej dhau 13 teev

- Txhawb ib zaug - noj txhua hnub

- Cov tshuaj ntshav ruaj khov, kom tsis txhob muaj qhov hloov pauv loj heev

** II. Kev xaiv agonist zoo heev ntawm GLP-1 receptors: **

- Txhim kho cov tshuaj insulin

- inhibits glucagon

- Ua rau lub plab zom mov qeeb

- Txhim kho cov cim qhia kev qab los noj mov

Cov txheej txheem no ua rau nws lub hnub qub peptide nrog ob qho tib si cov ntshav qab zib txo qis thiab cov txiaj ntsig tswj qhov hnyav.

** III. Multifunctional metabolic txhim kho cov teebmeem: ** kev tshawb fawb soj ntsuam qhia tias liraglutide tuaj yeem txhim kho:

- Kev tswj ntshav qab zib

- Pancreatic muaj nuj nqi

- Lub cev hnyav thiab rog feem pua

- Cov cim qhia txog kev pheej hmoo plawv

- Tsis yog-Alcoholic fatty siab kab mob (NASH)

** IV. Qhov zoo ntawm raw khoom hmoov: **

- Siab thiab tswj tau purity

- Tsawg impurity peaks

- Zoo khov- kom qhuav ruaj khov

- Yooj yim los npaj rau hauv ntau hom tshuaj txhaj tshuaj

- Cov txheej txheem paub tab, muaj peev xwm loj - nplai ntau lawm

Cov txiaj ntsig no ua rau nws tus qauv kub ntawm GLP-1 tshuaj thoob ntiaj teb. Ntu 5 Cov Txheej Txheem Ntau Lawm thiab Kev Tswj Xyuas Purity

Liraglutide feem ntau yog npaj siv cov khoom siv -theem peptide synthesis (SPPS) technology. Cov txheej txheem tseem ceeb suav nrog:

Stepwise peptide saw elongation

Kev kho deprotection

Fatty acid chain coupling

Hydrofluoride kho thiab cleavage

Kev ua kom huv huv (rov qab -theem HPLC)

Lyophilization los npaj hmoov

Kev tswj kom zoo muaj xws li:

- HPLC purity testing

- MS molecular phaus pom zoo

- Kev txheeb xyuas qhov sib npaug ntawm Amino acid

- Kev tshuaj xyuas cov kuab tshuaj residual

- Kev tshawb nrhiav Endotoxin thiab microbial

High - cov ntaub ntawv raw zoo yuav tsum ua raws li ICH thiab pharmacopoeia cov cai kom muaj kev nyab xeeb thiab ua tau zoo ntawm cov qauv.

Ntu 5 Daim Ntawv Thov Cheeb Tsam

I. Kev Siv Kho Mob

Liraglutide feem ntau yog siv rau:

- Kev kho mob ntshav qab zib hom 2

- Kev tswj qhov hnyav hauv cov neeg mob rog lossis rog rog

- Metabolic Syndrome

- Tsis yog- cawv fatty siab kab mob

- Kev txhim kho ntawm cov kab mob plawv

II. Kev lag luam tshuaj siv

Siv nyob rau hauv kev tsim khoom ntawm:

- Txhaj cwj mem formulations

- Pre- cov koob txhaj tshuaj

- Siab -kawg lyophilized hmoov txhaj tshuaj

III. Kev tshawb fawb siv

Siv rau:

- GLP-1 taw qhia txoj kev tshawb fawb

- Kev txhim kho cov tshuaj metabolic tshiab

- Peptide engineering tshawb fawb

- Kev lees paub ntawm cov qauv tshuaj pharmacokinetic

IV. Txhim kho Novel Formulation Platforms

Liraglutide, vim nws cov qauv paub tab, kuj tseem siv rau hauv:

- Kev tshawb nrhiav ntev - ua kom ruaj khov - tso tawm cov qauv

- Subcutaneous microneedle thaj ua rau thaj

- Kev tshawb fawb ntawm qhov ncauj peptide carrier technology

Nws lub peev xwm yog deb ntawm kev tshawb nrhiav tag nrho.

Tshooj 6 Kev Cia thiab Kev Ruaj Ntseg

Liraglutide lyophilized hmoov yuav tsum ua tau raws li kev cia khoom nruj:

- Kub: 2 ~ 8℃yog qhov zoo

- Tiv thaiv los ntawm lub teeb thiab khaws cia

- Tiv thaiv los ntawm ya raws thiab oxidation

- Tsis txhob rov khov dua -thaw cycles

- Tom qab npaj cov tshuaj, khaws cia ntawm qhov kub thiab txias thiab siv sai li sai tau

Kev khaws cia kom zoo tuaj yeem ua rau nws lub neej txee thiab ua kom muaj kev ruaj ntseg.

Ntu 7 Xaus

Raws li ib qho tseem ceeb ntawm peptide ntawm GLP-1 receptor agonists, liraglutide tau ua kom pom kev ua tau zoo hauv cov khoom siv raw engineering, cov teebmeem tshuaj, thiab kev tsim kho. Los ntawm cov qauv peptide optimization mus rau ntev - ua fatty acid hloov kho, thiab tom qab ntawd mus rau kev npaj cov hmoov lyophilized siab, nws tau dhau los ua ib qho tseem ceeb hauv cov kab mob metabolic. Kev nkag siab zoo ntawm liraglutide los ntawm kev xav ntawm kev tsim khoom, R & D, kev siv tshuaj kho mob, thiab cov qauv hauv qab yuav tso cai rau kev ua tiav zoo ntawm nws cov txiaj ntsig loj hauv kev kho mob thiab kev tshawb fawb.